[Randomized double-blind study of therapy of sudden deafness: initial results].
Three treatment groups (hydroxyethyl starch-pentoxifylline (HAES-steril/Trental), hydroxyethyl starch-pentoxifylline-naftidrofuryl (HAES-steril/Trental/Dusodril) and dextran-pentoxifylline (Rheomacrodex/Trental] and a placebo therapy control group (normal saline) were compared in a prospective randomised study (102 patients) and a retrospective study (292 patients). The trial therapy results were the same in all groups. However all treatments on patients with a haemoglobin greater than 14 g/l result in a significant hearing improvement compared with the placebo. The patient group with systolic blood pressure greater than 130 mm Hg treated with hydroxyethyl starch-pentoxifylline had a significant hearing improvement compared with the placebo, hydroxyethyl starch-pentoxifylline-naftidrofuryl and dextran-pentoxifylline. With increasing systolic blood pressure, patients in the placebo, hydroxyethyl starch-pentoxifylline-naftidrofuryl and dextran-pentoxifylline groups had a statistically significant worse result.
Desloovere
C
C
Zentrum Hals-Nasen-Ohrenheilkunde, J.W. Goethe-Universität Frankfurt am Main.
Meyer-Breiting
E
E
von Ilberg
C
C
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D002648:Child; D002986:Clinical Trials as Topic; D003911:Dextrans / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D003639:Hearing Loss, Sudden / Q000188:drug therapy*; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009257:Nafronyl / Q000627:therapeutic use; D010431:Pentoxifylline / Q000627:therapeutic use; D011446:Prospective Studies; D011897:Random Allocation; D012189:Retrospective Studies
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives; D009257:Nafronyl; D010431:Pentoxifylline
Randomisierte Doppelblindstudie zur Hörsturztherapie: Erste Ergebnisse.